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Colon tumours recapitulate embryonic transcription<p>Colon t mors from four indepe dent mouse models and 100 human colorectal cancers all exhibited striking recapitulation of embry-onic c gene expressi n from embryonic days 13.5-18.5.</p>
Abstract
Background: The expression of carcino-embryonic antigen by colorectal cancer is an example of
oncogenic activation of embryonic gene expression. Hypothesizing that oncogenesis-recapitulating-
ontogenesis may represent a broad programmatic commitment, we compared gene expression
patterns of human colorectal cancers (CRCs) and mouse colon tumor models to those of mouse
colon development embryonic days 13.5-18.5.
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R131.2 Genome Biology 2007,     Volume 8, Issue 7, Article R131       Kaiser et al. http://genomebiology.com/2007/8/7/R131Results: We report here that 39 colon tumors from four independent mouse models and 100
human CRCs encompassing all clinical stages shared a striking recapitulation of embryonic colon
gene expression. Compared to normal adult colon, all mouse and human tumors over-expressed
a large cluster of genes highly enriched for functional association to the control of cell cycle
progression, proliferation, and migration, including those encoding MYC, AKT2, PLK1 and SPARC.
Mouse tumors positive for nuclear β-catenin shifted the shared embryonic pattern to that of early
development. Human and mouse tumors differed from normal embryonic colon by their loss of
expression modules enriched for tumor suppressors (EDNRB, HSPE, KIT and LSP1). Human CRC
adenocarcinomas lost an additional suppressor module (IGFBP4, MAP4K1, PDGFRA, STAB1 and
WNT4). Many human tumor samples also gained expression of a coordinately regulated module
associated with advanced malignancy (ABCC1, FOXO3A, LIF, PIK3R1, PRNP, TNC, TIMP3 and
VEGF).
Conclusion: Cross-species, developmental, and multi-model gene expression patterning
comparisons provide an integrated and versatile framework for definition of transcriptional
programs associated with oncogenesis. This approach also provides a general method for
identifying pattern-specific biomarkers and therapeutic targets. This delineation and categorization
of developmental and non-developmental activator and suppressor gene modules can thus facilitate
the formulation of sophisticated hypotheses to evaluate potential synergistic effects of targeting
within- and between-modules for next-generation combinatorial therapeutics and improved mouse
models.
Background
The colon is composed of a dynamic and self-renewing epi-
thelium that turns over every three to five days. It is generally
accepted that at the base of the crypt, variable numbers
(between 1 and 16) of slowly dividing, stationary, pluripotent
stem cells give rise to more rapidly proliferating, transient
amplifying cells. These cells differentiate chiefly into post-
mitotic columnar colonocytes, mucin-secreting goblet cells,
and enteroendocrine cells as they migrate from the crypt base
to the surface where they are sloughed into the lumen [1]. Sev-
eral signaling pathways, notably Wnt, Tgfβ, Bmp, Hedgehog
and Notch, play pivotal roles in the control of proliferation
and differentiation of the developing and adult colon [2].
Their perturbation, via mutation or epigenetic modification,
occurs in human colorectal cancer (CRC) and the instillation
of these changes via genetic engineering in mice confers a cor-
respondingly high risk for neoplasia in the mouse models.
Moreover, tumor cell de-differentiation correlates with key
tumor features, such as tumor progression rates, invasive-
ness, drug resistance and metastatic potential [3-5].
A variety of scientific and organizational obstacles make it a
challenging proposition to undertake large-scale compari-
sons of human cancer to the wide range of genetically engi-
neered mouse models. To evaluate the potential of this
approach to provide integrated views of the molecular basis of
cancer risk, tumor development and malignant progression,
we have undertaken a comparative analysis of a variety of
individually developed mouse colon tumor models (reviewed
in [6,7]) to human CRC. The ApcMin/+ (multiple intestinal
neoplasia) mouse model harbors a germline mutation in the
Apc tumor suppressor gene and exhibits multiple tumors in
the small intestine and colon [8]. A major function of APC is
to regulate the canonical WNT signaling pathway as part of a
β-catenin degradation complex. Loss of APC results in a fail-
ure to degrade β-catenin, which instead enters the nucleus to
act as a transcriptional co-activator with the lymphoid
enhancer factor/T-cell factor (LEF/TCF) family of transcrip-
tion factors [9]. The localization of β-catenin within the
nucleus indicates activated canonical WNT signaling. In addi-
tion to germline APC mutations that occur in persons with
familial adenomatous polyposis coli (FAP) and ApcMin/+ mice,
loss of functional APC and activation of canonical WNT sign-
aling occurs in more than 80% of human sporadic CRCs [10].
Similar to the ApcMin/+ model, tumors in the azoxymethane
(AOM) carcinogen model, which occur predominantly in the
colon [11], have signaling alterations marked by activated
canonical WNT signaling.
Two other mouse models that carry different genetic altera-
tions leading to colon tumor formation are based on the
observation that transforming growth factor (TGF)β type II
receptor (TGFBR2) gene mutations are present in up to 30%
of sporadic CRCs and in more than 90% of tumors that occur
in patients with the DNA mismatch repair deficiency associ-
ated with hereditary non-polyposis colon cancer (HNPCC)
[12]. In the mouse, a deficiency of TGFβ1 combined with an
absence of T-cells (Tgfb1-/-; Rag2-/-) results in a high occur-
rence of colon cancer [13]. These mice develop adenomas by
two months of age, and adenocarcinomas, often mucinous, by
three to six months of age. Immunohistochemical analyses of
these tumors are negative for nuclear β-catenin, suggesting
that TGFβ1 does not suppress tumors via a canonical WNT
signaling-dependent pathway. The SMAD family proteins areGenome Biology 2007, 8:R131
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TGFβ signaling, in part through the TGFβ type II receptor.
Smad3-/- mice also develop intestinal lesions that include
colon adenomas and adenocarcinomas by six months of age
[14].
To identify transcriptional programs that are significantly
activated or repressed in different colon tumor models, we
compared gene expression profiles of 100 human CRCs and
39 colonic tumors from the four models of colon cancer to
mouse embryonic and mouse and human adult colon. The
results of these analyses demonstrate that tumors from the
mouse models extensively adopt embryonic gene expression
patterns, irrespective of the initiating mutation. Although two
of the mouse tumor subtypes were distinguishable by their
relative shifts towards early or later stages of embryonic gene
expression (driven principally by localization of β-catenin to
the nucleus versus the plasma membrane), Myc was over-
expressed in tumors from all four tumor models. Further, by
mapping mouse genes to their corresponding human
orthologs, we further show that human CRCs share in the
broad over-expression of genes characteristic of colon embry-
ogenesis and the up-regulation of MYC, consistent with a fun-
damental relationship between embryogenesis and
tumorigenesis. Large scale similarities could also be found at
the level of developmental genes that were not activated in
either mouse or human tumors. In addition, there were tran-
scriptional modules consistently activated and repressed in
human CRCs that were not found in the mouse models. Taken
together, this cross-species, cross-models analytical
approach - filtered through the lens of embryonic colon devel-
opment - provides an integrated view of gene expression pat-
terning that implicates the adoption of a broad program
encompassing embryonic activation, developmental arrest,
and failed differentiation as a fundamental feature of the biol-
ogy of human CRC.
Results
Strategy for cross-species analysis
Our strategy for the characterization of mouse models of
human CRC (Figure 1) relies on gene expression differences
and relative patterning across a range of mouse CRC models,
normal mouse colon developmental stages, and human CRCs.
Achieving this comparison was facilitated by the use of refer-
ence RNAs from whole-mouse and normal adult colon refer-
ence RNAs for both mouse and human measurements. Mouse
tumor samples were profiled on cDNA microarrays using the
embryonic day (E)17.5 whole mouse reference RNA identical
to that used previously [15] to examine embryonic mouse
colon gene expression dynamics from E13.5 to E18.5, during
which time the primitive, undifferentiated, pseudo-stratified
colonic endoderm becomes a differentiated, single-layered
epithelium. This strategy allowed us to construct a gene
expression database of mouse colon tumors in which gene
expression levels of the tumors could be referenced, ranked,
and statistically compared to an average value among the
tumors or to embryonic or adult colon gene expression levels
on a per-gene basis. First, we compared the four models with
each other, then to mouse colon development, and finally to
human CRCs using gene ortholog mapping (Figure 1).
Mouse colon tumors partition into classes reflecting 
differential canonical WNT signaling activity
To discover gene expression programs underlying differences
between etiologically distinct mouse models of CRC, gene
expression level values for each transcript in each tumor sam-
ple was set to its ratio relative to its median across the series
of tumor models. Using non-parametric statistical analyses,
1,798 cDNA transcripts were identified as differentially
expressed among the four mouse models of CRC. Five major
gene patterns were identified using K-means clustering (clus-
ters C1-C5; Figure 2a, top). Genes belonging to these clusters
were strongly associated with annotated gene function cate-
gories (see Table 1 for detailed biological descriptions and
associations). For example, cluster C1, composed of tran-
scripts that exhibited lower expression in Smad3-/- tumors
and higher expression in AOM, ApcMin/+ and Tgfb1-/-; Rag2-/
- tumors, contains 391 transcripts, including Cdk4, Ctnnb1,
Myc, Ezh2, Mcm2 and Tcf3. Gene list over-representation
analysis using Ingenuity Pathway Analysis applications dem-
onstrated highly significant associations to cell cycle progres-
sion, replication, post-transcriptional control and cancer.
Similarly, cluster C2, composed of 663 transcripts that exhib-
ited high expression in AOM and ApcMin/+ tumors, but low in
Smad3-/- and Tgfb1-/-; Rag2-/- tumors, included transcripts
for contact growth inhibition (Metap1, Pcyox1), mitosis (Mif,
Pik1), cell cycle progression and checkpoint control (Id2,
Ptp4A2, Tp53).
From the 1,798 transcripts differentially expressed among the
four mouse models of CRC, more than 70% (n = 1265) distin-
guished ApcMin/+ and AOM tumors versus Smad3-/- and
Tgfb1-/-; Rag2-/- tumors (Figure 2a, bottom). If a random or
equivalent degree of variance occurred among all classes,
there would be far less overlap. The majority of this signature
(approximately 75%, n = 904 features) derived from genes
over-expressed in ApcMin/+ and AOM tumors relative to the
Smad3-/- and Tgfb1-/-; Rag2-/- tumors (cluster C6). Cluster C6
was functionally enriched for genes linked to canonical WNT
signaling (Table 1). These included genes previously identi-
fied to be part of this pathway (Cd44, Myc, Stra6, Tcf1, Tcf4
[16], Id2, Lef1, Nkd1, Nlk, Twist1 [17], Catnb, Csnk1a1,
Csnk1d, Csnk1e, Plat, Wif1) as well as genes that appear to be
novel canonical WNT signaling targets (for example, Cryl1,
Expi, Ifitm3l, Pacsin2, Sox4 [16], Ets2, Hnrnpg, Hnrpa1, Id3,
Kpnb3, Pais, Pcna, Ranbp11, Rbbp4, Yes [18], Hdac2 [19]).
Moreover, consistent with the over-expression of Myc in
tumors from the ApcMin/+ and AOM models, we detected
enrichment of Myc targets, such as Apex, Eef1d, Eif2a, Eif4e,
Hsp90, Mif, Mitf, Npm1 [20], and the repression of Nibam
[20].Genome Biology 2007, 8:R131
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models
To establish a molecular basis for over-expression of canoni-
cal WNT target genes in ApcMin/+ and AOM tumors, we used
immunohistochemistry to characterize the relative cellular
distribution of β-catenin. Tumors from ApcMin/+ (Figure 2b,
bottom left panel) and AOM (not shown) mice exhibited
strong nuclear β-catenin immunoreactivity and reduced mem-
brane staining (see inset), whereas tumors from Smad3-/-
(Figure 2b, bottom right panel) and Tgfb1-/-; Rag2-/- (not
shown) mice showed strong plasma membrane β-catenin
staining with no nuclear accumulation (see inset). Additional
tests to confirm the microarray results were also carried out
using an independent set of C57BL/6 ApcMin/+ colon tumor
samples analyzed by quantitative real-time PCR (qRT-PCR;
Figure 3a) and immunohistochemistry (Figure 3b). All
expression patterns identified via microarray analysis were
consistent with the qRT-PCR results (n = 9 transcripts, cho-
sen for their demonstration of a range of differential expres-
sion characteristics). In situ hybridization analyses using
C57BL/6 ApcMin/+ colon tumor samples also validated that
Wif, Tesc, Spock2 and Casp6 were strongly expressed in dys-
plastic cells of the tumors (data not shown). At the protein
level, immunohistochemical analyses confirmed relatively
greater expression of the oncoprotein stathmin 1 in ApcMin/+
mice and tyrosine phosphatase 4a2 in Smad3-/- mice (Figure
3b).
Overall, cluster C6 genes (that is, genes with greater up-regu-
lation in tumors from ApcMin/+ and AOM models than in
Smad3-/- and Tgfb1-/-; Rag2-/-) were consistent with
increased tumor cell proliferation (for example, Myc, Pcna),
cytokinesis (for example, Amot, Cxcl5), chromatin remode-
ling (for example, Ets2, Hdac2, Set) as well as cell cycle pro-
gression and mitosis (for example, Cdk1, Cdk4, Cul1, Plk1). It
is important to note that Myc is up-regulated in all four
mouse tumor models relative to normal colon tissue (see
below). Biological processes showing increased transcription
in tumors from the Smad3-/- and Tgfb1-/-; Rag2-/- models
(cluster C7) included immune and defense responses (for
example, Il18, Irf1, Myd88), endocytosis (for example, Lrp1,
Ldlr, Rac1), transport (for example, Abca3, Slc22a5,
Slc30a4), and oxidoreductase activity (for example, Gcdh,
Prdx6, Xdh) (Table 1). Taken together, these transcriptional
observations are both consistent with and extend our under-
standing of the histological features of the CRC models [7].
For example, while ApcMin/+ and AOM tumors are character-
ized by cytologic atypia (that is, nuclear crowding, hyperchro-
masia, increased nucleus-to-cytoplasm ratios and minimal
inflammation), tumors from Smad3-/- and Tgfb1-/-; Rag2-/-
mice show less overt dysplastic changes but exhibit a signifi-
cant inflammatory component.
Stratification of murine colon tumor models by localization of β-catenin and plan for analysisFigure 1
Stratification of murine colon tumor models by localization of β-catenin and plan for analysis. Colon tumors from four etiologically distinct mouse models 
of CRC were subjected to microarray gene expression profiling. The gene expression profiles from the different mouse model tumors were compared 
and contrasted to each other, as well as to those from embryonic mouse colon development and 100 human CRCs.
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Detailed cluster analysis: differential and statistically significant biological functions in clusters C1-C7
Cluster no. Number of
transcripts/
ProbeSets (PS)
Reference Pattern Biology Example genes
1 391 Global Up (A/M/T);
down (S)
RNA post-transcriptional modification, cell 
cycle, DNA replication/recombination/
repair, molecular transport, post-
translational modification, cellular assembly 
and organization, cellular movement, 
cardiovascular system development and 
function, connective tissue development 
and function, cancer
Cell cycle progression (Cdk4, Ctnnb1, Id1, 
Id3, Myc, Pcna, Tcf3), replication of DNA 
(Idi1, Mcm2, Myc, Orc4l, Pcna, Polb, Set), 
checkpoint control (Bub3, Myc, Rae1, 
Smc1l1), invasion of mammary epithelial 
cells (Ezh2), recovery of ATP (Hspd1, 
Hspe1), hyperplasia of secretory structure 
(Cdk4, Ctnnb1, Ptpre, Sdc1), cell 
proliferation (Id1, Id3, Myc, Pcna)
2 663 Global Up (A/M); 
down (S/T)
Cell cycle, cellular response to 
therapeutics, cellular assembly and 
organization, molecular transport, 
connective tissue development and 
function, genetic disorder, gastrointestinal 
disease, cancer, Wnt-signaling pathway
Contact growth inhibition of connective 
tissue cells (Metap2, Pcyox1), mitosis of 
tumor cells (Mif, Plk1), cell cycle 
progression (Id2, Tp53), checkpoint control 
(Mad2l1, Tp53), DNA modification (Apex1, 
Dnmt3a, Dnmt3b), infiltrating duct 
carcinoma (Esr1, Ing4), mitosis of tumor 
cells (Mif, Plk1), myotonic dystrophy 
(Dmpk, Znf9), Wnt-signaling (Csnk1d, 
Csnk1e, Lef1, Nlk, Tcf3, Tcf4, Wif1)
3 170 Global Up (A/S); 
down (M/T)
Cancer, cell death, cellular development, 
cellular growth and proliferation, cell cycle
Apoptosis of colon carcinoma cells 
(Tnfsf10), sarcoma (Ewsr1, Mdm2, Tnfsf10), 
hyperpoliferation (Map2k7), survival 
(Mdm2, Nras, Tnfsf10), tumorigenesis 
(Ewsr1, Mdm2, Nras, Tnfsf10), fibroblast 
proliferation (Arid5b, E4f1, Map2k7, Mdm2, 
Nras), mitosis of embryonic cells (E4f1)
4 142 Global Up (M/S); 
down (A/T)
Cellular movement, hematological system 
development and function, immune 
response, hematological disease, immune 
and lymphatic system development and 
function, organ morphology, cell-to-cell 
signaling and interaction, cell death, 
molecular transport
Cell movement/chemotaxis (Alox5AP, C3, 
Ctsb, Cxcl12, Dcn, Fcgr3a, Fgfr1, Hif1a, 
Igf2, Itgb2, Lsp1, S100A9, Slp1), invasion of 
tumor cell lines (Cbx5, Ctsb, Cxcl12, Fstl1, 
Hif1a, Ighg1, Igf2, Itgb2), chemotaxis/
migration of leukocytes (C3, Cxcl12, Icam2, 
Itgb2, Lgals1, Lsp1, S100a9, Slpi), growth of 
tumor (Fgfr1, Hif1a, Igf2, Igfbp5, Ighg1), 
invasion of tumor cell lines (Cbx5, Ctsb, 
Cxcl12, Fstl1, Hif1a, Igf2, Ighg1, Itgb2)
5 432 Global Up (S/T); 
down (A/M)
Cell death, neurological disease, drug 
metabolism, endocrine system 
development and function, cancer, drug 
metabolism, lipid metabolism, 
gastrointestinal disease, organismal 
functions, organismal injury and 
abnormalities
Gut epithelium differentiation (Chgb, Klf4, 
Klf6, Sst), cell death/apoptosis of microglia 
(Btg1, Casp3, Casp9, Cx3cl1, Grin1, 
Myd88), uptake of prostaglandin E2 
(Slco2a1), tumorigenesis of brain tumor 
(Nf2, Stat2), tumorigenesis of polyp (Asph, 
Smad4), aggregatability of colon cancer cell 
lines (Cd82), cell spreading of colon cancer 
cell lines (Smad4), contact inhibition of 
colon cancer cell lines (Prkg1)
6 904 Global Up (A/M); 
down (S/T)
Cell proliferation, cell cycle progression and 
mitosis, DNA replication/recombination/
repair, molecular transport, RNA post-
transcriptional modification, post-
translational modification, cellular growth 
and proliferation, connective tissue 
development and function, cancer, 
gastrointestinal disease, digestive system 
development and function
Cell cycle progression/proliferation (Cdk4, 
Clu, Id2, Mki67, Magoh, Myc, Pcna, Tcf3, 
Tp53), tumor cell mitosis (Mif, Plk1), DNA 
excision repair (Apex1, Ddb1, Hmgb1, 
Polb), DNA methylation (Dnmt3a, 
Dnmt3b), accumulation of colonocytes 
(Clu, Myc), tumorigenesis (Cd44, Cdk4, 
Ctnnb1, Esr1, Myc, Prkar1a, Tp53), Wnt-
signaling pathway (Csnk1a1, Cskn1d, 
Cskn1e, Ctnnb1, Lef1, Myc, Nlk, Ppp2cb, 
Tcf3, Tcf4, Wif1)Genome Biology 2007, 8:R131
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transcriptome in mouse tumor models
We hypothesized that comparisons of genes over-expressed
in both colon tumors and embryonic mouse colon could
provide valuable insights into tumor programs important for
fundamental aspects of tumor growth and regulation of dif-
ferentiation. To identify genes and observe regulatory pat-
terns that were shared or differed between colon tumors and
embryonic development, we applied a global quantitative ref-
erencing strategy to both tumor and embryonic samples by
calculating the relative expression of each gene as the ratio of
its expression in any sample as that relative to its mean level
in adult colon. From this adult baseline reference, genes over-
expressed in the four mouse tumor models appeared strik-
ingly similar. Moreover, the vast majority of genes over-
expressed in tumors were also over-expressed in embryonic
colon (Figure 4a). If the fraction of fetal over-expressed genes
from the entire microarray (5,796 of 20,393 features; 28.4%)
was maintained at a similar occurrence frequency in the
tumor over-expressed fraction (8,804 of 20,393), one would
expect an overlap of 2,502 transcripts ((8,804/20,393) ×
28.4%). Rather, 4,693 out of the 5,796 fetal over-expressed
transcripts were observed to be over-expressed in the 8,804
tumor over-expressed genes (Figure 4b). The probability cal-
culated by Fisher's exact test is p < 1-300, and thus represents
highly significant over-representation of fetal genes among
the tumor over-expressed genes. Similarly, genes under-
expressed in developing colon were disproportionately
underexpressed in tumors relative to normal adult colon
(3,282 of 3,541; p < 1-300). Combining these results, approxi-
mately 85% of the developmentally regulated transcripts
(7,975 out of 9,337 features) were recapitulated in tumor
expression patterns relative to adult colon (Figure 4a,b, green
and red markers represent the corresponding 7,975 features).
To explore the potential biological significance of genes over-
expressed in both embryonic colon development and mouse
tumors, we used K-means clustering to generate C8-C10 clus-
ter patterns as shown in a hierarchical tree heatmap (Figure
4c; Table 2). Several sub-patterns were evident, some of
which clearly separated ApcMin/+ and AOM from Smad3-/- and
Tgfb1-/-; Rag2-/- tumors. One strong cluster, cluster C8, con-
sisted of genes more strongly expressed in ApcMin/+ and AOM
than Smad3-/- and Tgfb1-/-; Rag2-/- tumors. This group of
genes represented a large fraction of all differences found
between nuclear β-catenin-positive (ApcMin/+ and AOM) and
negative (Smad3-/- and Tgfb1-/-; Rag2-/-) tumors (approxi-
mately 45%; 1,636 out of 3,592 features), as well as differ-
ences detected between early (that is, E13.5-E15.5, ED) and
late (E.16.5-E18.5, LD) embryonic colon developmental
7 361 Global Up (S/T); 
down (A/M)
Cell death, neurological disease, cancer, 
drug metabolism, embryonic development, 
endocrine system development and 
function, lipid metabolism, organismal injury 
and abnormalities, infectious disease, 
immune response, immunological disease, 
hematological disease; gastrointestinal 
disease; antigen +presentation pathway
Antigen presentation (B2m, Cd74, H2-D1, 
HLA-DMA, HLA-DRB, Psmb8, Tap2), 
embryonic development (C3, Celsr1, 
Erbb3, Impk, Mcl1), infectious disease (B2m, 
Ifngr1, Irf1, Myd88, Nr3c1), mast cell 
chemotaxis (C3, Cx3cl1), apoptosis of 
microglia (Btg1, Casp3, Cx3cl1, Myd88), 
tumorigenesis of polyp (Asph, Smad4), 
transport of prostaglandin E2 (Slco2a1), 
quantity of colonocytes (Guca2a), 
gastrointestinal disease (Asph, Cd84, 
Smad4)
A, AOM-induced; M, ApcMin/+; S, Smad3-/-; T, Tgfb1-/-; Rag2-/-.
Table 1 (Continued)
Detailed cluster analysis: differential and statistically significant biological functions in clusters C1-C7
Active canonical WNT signaling (as determined by nuclear β-catenin) stratifies the four murine colon tumor models into two groupsFigure 2 (see following page)
Active canonical WNT signaling (as determined by nuclear β-catenin) stratifies the four murine colon tumor models into two groups. (a) Hierarchical 
clustering of gene transcripts separates the four models into two groups. The upper panel shows 1,798 gene transcripts identified as differentially 
expressed among any of the four mouse tumor models (Kruskal-Wallis test + Student-Newman-Keuls test + FDR < 5.10-5). Results demonstrate that 
AOM (A) and ApcMin/+ (M) tumors are transcriptionally more similar to each other than to tumors from Smad3-/- (S) and Tgfb1-/-; Rag2-/- (T) mice. Five 
clusters have been identified (C1-C5) that correspond to the K-means functional clusters listed in Table 1. Please refer to Table 1 for an in-depth 
description of the functional classification of the genes found in these clusters. The lower panel illustrates the extent of the similarity between A/M and S/
T tumors by identifying the top-ranked 1,265 transcripts of the 1,798 that were higher or lower in the two tumor super-groups (rank based on Wilcoxon-
Mann-Whitney test for between-group differences with a FDR < 5.10-5 cutoff). Up-regulated transcripts in A/M tumors are highly enriched for genes 
associated with canonical WNT signaling activity, cell proliferation, chromatin remodeling, cell cycle progression and mitosis; transcripts over-expressed in 
S/T tumors are highly enriched for genes related to immune and defense responses, endocytosis, transport, oxidoreductase activity, signal transduction 
and metabolism. (b) Representative histologies for each of the four tumor models. The lower panel illustrates the model-dependent localization of β-
catenin. Tumors from M (bottom left) and A (not shown) mice exhibited prominent nuclear β-catenin accumulation and reduced cell surface staining. 
Conversely, tumors from S (bottom right) and T(not shown) mice exhibited retention of plasma membrane β-catenin immunoreactivity. A and M in top 
panel 100× magnification; S and T 200× magnification. M and S in lower panel both 400× magnification.Genome Biology 2007, 8:R131
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that are more characteristic of the earlier stages of normal
colon development (E13.5-E15.5), are clearly expressed at
higher levels in nuclear β-catenin-positive tumors. This
observation is illustrated by 750 transcripts selected solely for
stronger expression in ED versus LD (Figure 4d). Note that
most of these transcripts overlap with cluster C6 containing
230 features (Figure 2a, lower panel) and illustrate the ten-
dency of the earlier-expressed developmental genes to be
more strongly expressed in ApcMin/+ and AOM mice. In addi-
tion, transcripts associated with increased differentiation and
maturation, observed at later stages of colon development
E16.5-E18.5 (for example, Klf4 [21], Crohn's disease-related
Slc22a5/Octn2 [22], Slc30a4/Znt4 [23], Sst [24]), were
expressed at higher levels by tumors from Smad3-/- and
Tgfb1-/-; Rag2-/- mice.
Human CRCs reactivate an embryonic gene signature
Since mouse tumors recapitulated developmental signatures
irrespective of their etiology, we asked whether a similar com-
mitment to embryonic gene programming was shared by spo-
radic human CRCs. Tumor classification by microarray
profiling is usually accomplished by referencing relative gene
expression levels to the median value for each gene across a
series of tumor samples. Using this 'between-tumors median
normalization' approach, as well as a gene filtering strategy
that detects significantly regulated genes in at least 10% of the
cases, led to the identification of a set of 3,285 probe sets cor-
responding to transcripts whose expression was highly varied
between independent human tumor cases. As shown in Fig-
ure 5, there was striking heterogeneity of gene expression
among 100 human CRCs. For example, cluster 15 contained a
set of genes (principally metallothionein genes) recently iden-
tified to be predictive of microsatellite instability [25,26].
This analysis indicates that human CRCs have a greater level
of complexity than the mouse colon tumors studied here
(compare Figures 2 and 5). There was no correlation between
these distinguishing clusters and the stage of the tumor (note
the broad overlapping distributions of Dukes stages A-D
across these different clusters). However, as shown in Table
3, gene ontology and network analysis of the individual gene
clusters (clusters C11-C17) that were differentially active in
subgroups of the tumors, map to genes highly associated with
a diverse set of biological functions, including lipid metabo-
lism, digestive tract development and function, immune
response and cancer
To evaluate if similar sets of genes are systematically acti-
vated or repressed in human CRC, as in the mouse colon
tumors, we undertook two procedures to align the data. First,
gene expression values for the mouse and human tumors
were separately normalized and referenced relative to their
respective normal adult colon controls; second, mouse and
human gene identifiers were reduced to a single ortholog
gene identifier. The latter is a somewhat complex procedure
that requires identifying microarray probes from each plat-
form that can be mapped to a single gene ortholog and
undertaking a procedure to aggregate redundant probes
within a platform (see Materials and methods). This
approach allowed the identification of 8,621 gene transcripts
on the HG-U133 plus2 and Vanderbilt NIA 20 K cDNA arrays
for which relative expression values could be mapped for
nearly all mouse and human samples. A clustering-based
assessment of expression across the whole mouse-human
ortholog gene set identified a large number of transcripts
behaving similarly across colon tumors, many irrespective,
but some respective of species. Notably, the great majority of
genes over-expressed in all tumors were also over-expressed
during colon development (Figure 6a). To evaluate the statis-
tical significance of this pattern, we used a Venn overlap fil-
tering strategy and Fisher's exact test analysis. Approximately
50% of the 2,212 ortholog genes over-expressed in at least
10% of the human cancers relative to adult colon were also
over-expressed in developing colon. If there was not a selec-
tion for developmental genes among those over-expressed in
tumors, the expected overlap would be (2,718/8,621) × 2,212
= 697 transcripts. Using Fisher's exact test for the significance
of the increased overlap of 1,080 versus 697 transcripts is p <
1e-300. Similarly, genes under-expressed in mouse colon
development and human CRCs also strongly overlapped (Fig-
ure 6b; 431 of 737, p < 1e-76). This result is significantly
greater than the 8-19% of genes that were estimated to be
over-expressed in human colon tumors and fetal gut morpho-
genesis based upon a computational extrapolation of SAGE
data [27]. Thus, our findings not only confirm but also signif-
icantly expand and experimentally validate the previously
suggested recapitulation of embryonic signatures by human
CRCs.
Selective validation of microarray results by qRT-PCR and immunohistochemistryFigure 3 (see following page)
Selective validation of microarray results by qRT-PCR and immunohistochemistry. Differential expression of transcripts identified by the microarray 
analyses was examined using (a) qRT-PCR and (b) immunohistochemistry. Additional colon tumors from five ApcMin/+ (M; nuclear β-catenin-positive) mice 
and four Smad3-/- (S; nuclear β-catenin-negative) mice were harvested, and qRT-PCR was performed on nine genes that exhibited representative strong or 
subtle patterns in the microarray analyses. All nine patterns detected in the microarray set were validated by the qRT-PCR results. Alox12, Arachidonate 
12-lipoxygenase; Casp6, Caspase 6; Matn2, Matrilin 2; Ptplb, Protein tyrosine phosphatase-like B; Sox21, SRY (sex determining region Y)-box 21; Spock2, 
Sparc/osteonectin, CWCV, and Kazal-like domains proteoglycan (testican) 2; Tesc, Tescalcin; Tpm2, Tropomysin 2; Wif1, WNT inhibitory factor; Stmn1, 
stathmin 1; Ptp4a2, phosphatase 4a2. In (a), *p < 0.05 and **p < 0.01.Genome Biology 2007, 8:R131
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nAll overlaps between tumor expression and development
were pooled to form a set of 2,116 ortholog gene transcripts.
This was subjected to hierarchical tree and K-means cluster-
ing to define six expression clusters, C18-C23 (Figure 6c;
Table 4). These clusters provide an impressive partitioning of
groups of genes associated with different biological functions
critical for colon development, maturation and oncogenesis.
Cluster C22 (860 transcripts of genes strongly expressed both
developmentally and across all tumors) is highly enriched
with genes associated with cell cycle progression, replication,
cancer, tumor morphology and cellular movement. Cluster
C18 (258 transcripts down-regulated in mouse and human
tumors, as well as in development) is highly enriched in genes
associated with digestive tract function, biochemical and lipid
metabolism. This cluster is clearly composed of genes associ-
ated with the mature GI tract. Thus, as opposed to recapitu-
lating developmental gene activation, the cluster C18 pattern
indicates a corresponding arrest of differentiation in both
mouse and human tumors. Cluster C23 (142 transcripts over-
expressed in all mouse models and human CRC, but with low
All four murine tumor models exhibit reactivation of embryonic gene expressionFigure 4 (see previous page)
All four murine tumor models exhibit reactivation of embryonic gene expression. The expression level of each gene in each sample was calculated relative 
to that in adult colon. Genes and samples were subjected to unsupervised hierarchical tree clustering for similarities among genes and tumors. (a) 
Heatmap shows the relative behaviors of 20,393 transcripts that passed basic signal quality filters with gene transcripts shown as separate rows and 
samples as separate columns. Note that the majority of genes over-expressed in tumors (red) are also over-expressed in embryonic colon; similarly, the 
genes under-expressed in tumors (blue) are under-expressed in embryonic colon. The color bars to the right indicate the position of 4,693 transcripts 
over-expressed in both tumors and development (red) or under-expressed in both (green). In addition, there are genes over-expressed in embryonic 
colon that are under-expressed in tumors and vice versa (asterisks). (b) The genes represented in (a) were divided into those over-expressed and under-
expressed in embryonic colon and in the tumors, respectively. Fisher's exact test was used to calculate expected overlaps between lists and confirmed 
significant over-representation of development-regulated signatures among the tumors (*p < 1-300, **p < 1.3-19, ***p < 4-296, ****p < 1-300). (c) Heatmap 
showing the behavior of a subset of the transcripts in (a) (n = 4,693 features) that were over-expressed in both embryonic colon and tumor samples. Refer 
to Table 2 for a complete description of the genes associated with these clusters. (d) Embryonic gene expression can be further refined into genes 
expressed differentially during early (ED; E13.5-15.5) and late (LD; E16.5-18.5) embryonic development. Heatmap showing the relative behaviors of 750 
transcripts that are highest-ranked for early versus late embryonic regulation. Overall, transcripts with the highest early embryonic expression were 
expressed at higher levels in nuclear β-catenin-positive tumors (A and M), whereas nuclear β-catenin-negative tumors (S and T) were representative of 
later stages of embryonic development. Sample groups: ED, early development (E13.5-E15.5); LD, late development (E16.5-E18.5); A, AOM-induced; M, 
ApcMin/+; T, Tgfb1-/-; Rag2-/-; S, Smad3-/-. Staging: nAC, normal colon. Clusters C8-C10 to the right of the heatmap correspond to the K-means functional 
clusters listed in Table 2.
Table 2
Detailed cluster analysis: differential and statistically significant biological functions in clusters C8-C10
Cluster no. Number of PS Reference Biology Example genes
8 1,240 Adult RNA post-transcriptional modification, cell cycle, 
cellular assembly and organization, DNA 
replication/recombination/repair, cancer, molecular 
transport, protein traffic and synthesis, cellular 
development, gastrointestinal disease, IGF-1 
signaling, Wnt-signaling
Mitosis (Ask, Birc5, Bcra1, Cdc2, Cdk4, Chek1, 
Mad2l1, Mif, Plk1), DNA mismatch repair (Hgmb1, 
Msh2, Pcna, Rev1l, Xrcc5), cell transformation 
(Cdc37, Id2, Myc), cell proliferation (Ctnnb1, Pcna, 
Plat, Plk1, Rala, Top2a), colorectal cancer (Birc5, 
Brca1, Cdc37, Myc, Top53), IGF-1 signaling (Igf1, 
Igfb4, Mapk1, Prkc, Ptpn11), Wnt signaling 
(Csnk1a1, Csnk2a1, Ctnnb1, Gs3kb, Myc, Nlk, 
Tcf3, Tcf4)
9 1,676 Adult Protein synthesis, RNA-post transcriptional 
modification, cancer, connective tissue 
development and function, embryonic 
development, organ morphology, tissue 
morphology, cell-to-cell signaling and interaction, 
tissue development
Protein synthesis (Csf1, Eif5, Gadd45g, Itgb1, Sars, 
Tnf, Traf6), transformation (Ccnd1), formation of 
hepatoma cell line (Hras, Pin1, Shfm1), cell growth 
(Nrp1, Tnf), invasion of lymphoma cell line (Itgb1, 
Itgb2), proliferation of ovarian cancer cell lines (Fst, 
Hras, Itgfb5, Sod2, Sparc), fibroblast cell cycle 
progression (Ccnf, E2f5, Hras, Map4, Rhoa, Skil), 
survival of epiblast (Dag1, Itgb1), cell adhesion 
(Icam1, Itgb1, Itgb2, Lu, Rhoa, Tnf)
10 1,051 Adult Cell cycle, cellular assembly and organization, DNA 
replication, recombination/repair, cellular function 
and maintenance, cancer, cardiovascular system 
development and function, gene expression, 
immunological disease, digestive system 
development and function, activin/inhibin signaling
Cell cycle (Cdk2, Ccnd3, Siah), exocytosis (Nos3, 
Snap23, Stx6, Vamp2), Burkitt's lymphoma (Dmtf1), 
cell transformation (Mmp2, Pecam1), angiogenesis 
(Mdk, Nos3), activation of RNA (Hrsp12, 
Rps6kb1), development of gastrointestinal tract 
(Pdgfra, Sptbn1), activin/inhibin signaling (Acvr2b, 
Bmpr1b, Inha, Map3k7, Mapk8, Tgfbr1)
PS, ProbeSets.Genome Biology 2007, 8:R131
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Detailed cluster analysis: differential and statistically significant biological functions in clusters C11-C17
Cluster no. Number of PS Reference Biology Example genes
11 167 Global Molecular transport, protein traffic, lipid 
metabolism, small molecule biochemistry, 
cardiovascular system development, dermatological 
diseases and conditions, organismal development, 
organismal injury and abnormalities, cancer, 
digestive system development and function
Protein excretion (BF, EDNRA, KL), 
corticosteroid/daunorubicin transport (ABCB1), 
modification of cholesterol (ABCB1, SULT2B1), 
neovasculariation of animal (TNFRSF6B, TNFSF11), 
angiogenesis of granulation tissue (PTGES), blister 
formation (COL17A1, FRAS1), development of 
enteroendocrine cells (NEUROD1), crypt size 
(FOLR1), connective tissue formation (EDNRA, 
IL7, MSX2, PTGES, WT1), division of mesenchymal 
cells (BMP7)
12 762 Global RNA post-translational modification, gene 
expression, cancer, renal and urological disease, 
RNA traffic embryonic development, cell-to-cell 
signaling and interaction, estrogen receptor 
signaling, EGF signaling, PI3K/AKT signaling
Processing of RNA (HNRPA2B1, HNRPD, 
HNRPH1, PRPF4B, RBM6, RBPMS, SFPQ, SFRS3, 
SFRS4, SNRPA1, U2AF1, ZNF638), transactivation 
of glucocorticoid/thyroid hormone response 
element (FOXO1A, NCOR1, NR3C1, RORA), 
tumorigenesis (CD44, CTNNB1, EGFR, NF1, 
PRKAR1A, PTEN, THBS1), adhesion of tumor cells 
(CD44, CD47, EGFR, PTK2, THBS1), juvenile/
colonic polyposis (CTNBB1, PTEN, SMAD4), 
IGF1-signalling (CTNBB1, FOXOA1, PTEN, SOS2)
13 213 Global Cell morphology, cellular development, 
hematological disease, genetic disorder, embryonic 
development, cellular assembly and organization, 
hair and skin development and function, 
cardiovascular system development and function, 
cancer, digestive system development and function
Conversion of epithelial cells (ATOH1, DMBT1, 
FOS), depolarization of cells (CACNA1C, FOS, 
NTS), development of Goblet/Paneth/
enteroendocrine cells (ATOH1), hematological 
disease (HBA1, HBA2, HBB, GIF), partington 
syndrome (ARX), muchopolysaccharidosis 
(HYAL1), Pfeiffer's syndrome (FGFR2), retinoic 
acid synthesis (ALDH1A1, ALDH1A2), adenoma 
inflammation (TFF1), density of connective tissue 
(MIA, TNFRSF11B)
14 161 Global Cancer, cellular movement, skeletal and muscular 
disorders, immune response, gastrointestinal 
disease lipid metabolism, reproductive system 
disease, small molecule biochemistry, digestive 
system development and function, tissue 
development
Migration/invasion of tumor cell lines (CDKN2A, 
CST6, DPP4, KITLG, LAMA3, LCK, MDK, 
SERPINB5, TFF2, TGFA), tumorigenesis of 
intestinal polyp (ASPH), proliferation of tumor cell 
lines (APRIN, CDKN2A, CST6, IMP3, LITLG, 
PIWIL1, SLP1, TGFA), cytotoxic reaction 
(CDKN2A, LCK), invasion of tumor cell lines 
(CDKN2A, CST6, DPP4, SERPINB5, TFF2, TGFA), 
tumorigenesis of small intestine (PLA2G4A), size/
tumorigenesis of polyp (ASPH, CDKN2A, TGFA)
15 366 Global Drug metabolism, endocrine system development 
and function, small molecule biochemistry, lipid 
metabolism, molecular transport, gene expression, 
cell death, cell morphology, cancer, gastrointestinal 
disease, digestive system development and 
function, tissue development
Steroid metabolism (AKR1C2, CYP3A5, 
UGT2B15, UGT2B17), conversion of progesterone 
(AKR1C3, HSD3B2), modification of dopamine 
(SULT1A3, XDH), oxidation of norepinephrine 
(MAOA), drug transport (ANCB1, ABCG2), 
transport of fludarabine (SLC28A2), 
hydrocortisone uptake (ABCB1), formation of 
aberrant crypt foci (NR5A2, PTGER4), cell death 
of enteroendocrine cells (GCG, PYY), growth of 
crypt cells (NKX2, NKX3)
16 221 Global Cardiovascular system development and function, 
cellular movement, hematological system 
development and function, immune response, 
cancer, neurological disease, carbohydrate 
metabolism, organismal development, digestive 
system development and function, tissue 
development
Cell movement/proliferation of endothelial cells 
(ADIPOQ, CXCL12, ENPP2, FGF13, HGF, HHEX, 
MYH11, PTN), formation of endothelial tube and 
blood vessel (ADAMTS1, ANGPTL1, CCL11, 
CXCL12, ENPP2, F13A1, HGF, MEF2C, MYH11, 
PTEN), cell movement of cancer cells (CXCL12, 
CD36, HGF, IGF1, L1CAM, SFRP1, PTN), 
tumorigenesis (AGTR1, CNN1, ENPP2, FGF7, 
HGF, IGF1, KIT, L1CAM), Hirschprung disease 
(EDNRB, L1CAM)Genome Biology 2007, 8:R131
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nexpression in development) maps to genes highly associated
with the disruption of basement membranes, invasion and
cell cycle progression, as well as altered transcriptional con-
trol. Cluster C21 (313 transcripts in which human tumors
somewhat variably express a set of genes that are rarely
expressed by the mouse tumors) is remarkable for its compo-
sition of genes associated with cell cycle proliferation, tissue
disruption and angiogenesis. Thus, while categorically quite
similar to cluster C23, the genes in cluster C21 represent a
separately regulated module that is enriched for genes
associated with invasion. Clusters C21 and C23 reveal sets of
genes likely involved in tumor progression. Cluster C22 (with
genes over-expressed in all mouse and human tumors and
strongly expressed in embryonic colon) represents a group of
genes highly correlated with transformation. The top-ranked
transcription factor present in this cluster, with regulation
independent of β-catenin localization, is Myc/MYC (Figure
7b). Although Myc was lower in expression in the Smad3-/-
tumors compared to tumors from the other three models, it
was elevated in all four models relative to normal adult colon.
Myc/MYC was over-expressed in all mouse and human
tumors as well as in development. This contrasts with Sox4,
which is unaltered in expression in the Smad3-/- and Tgfb1-/-;
Rag2-/- tumors but is up-regulated in AOM and ApcMin/+
tumors relative to normal adult colon (Figure 7b). Myc/MYC
over-expression may be independent of nuclear β-catenin
status. Increased Myc/MYC expression may reflect both acti-
vation of canonical Wnt signaling, as it is a target of nuclear
β-catenin/TCF [28], and deregulation of TGFβ signaling, as
TGFβ1 is known to repress Myc/MYC [29-31]. These observa-
tions suggest a fundamental role for Myc/MYC in colonic
neoplasia.
Discussion
Numerous mouse models of intestinal neoplasia have been
developed, each with unique characteristics. The models con-
structed to date, however, do not fully represent the complex-
ity of human CRCs principally because most are unigenic in
origin and produce primarily adenomas and early stage can-
cers. Although models like ApcMin/+ show molecular similari-
ties to human CRCs, such as initiation of adenoma formation
by inactivation of Apc, little is known about the molecular
similarities of tumors from the different mouse models. It is
also unknown how such common and perhaps large-scale
molecular changes in mouse models relate to the molecular
programming of human CRC. To shed light on the underlying
molecular changes in tumors from mouse models and human
CRC, we assessed the relationship at the molecular level of
four widely used, but genetically distinct, mouse models that
develop colon tumors. A subsequent analysis of the models in
the context of embryonic mouse colon development was also
undertaken. Finally, to identify consensus species-independ-
ent cancer signatures that may define gene expression
changes common to all CRCs, we projected relevant mouse
model signatures onto a large set of human primary CRCs of
varied histopathology and stage.
Differential canonical WNT signaling activity 
discriminates two major classes of mouse models of 
CRC with distinct molecular characteristics
Tumors from mouse models of CRC exhibit significant phe-
notypic diversity [6], and, therefore, were expected to exhibit
differential gene expression patterns. Using a combination of
inter-model and normal adult gene expression level referenc-
ing, our analysis of tumors from mouse models of CRC has
revealed a low complexity between models and strains, and
has identified common and unique transcriptional patterns
associated with a variety of biological processes and pathway-
associated activities. Our results demonstrate an imbalance
between proliferation and differentiation, with nuclear β-cat-
enin-positive tumors being more proliferative, less differenti-
ated and with lower immunogenic characteristics than
tumors from nuclear β-catenin-negative tumors. Mouse
tumors characterized by signatures of relative up-regulation
of genes associated with cell cycle progression also showed
increased canonical WNT signaling activity (ApcMin/+ and
AOM). Tumors from mouse models not showing canonical
WNT signaling pathway activation (Smad3-/- and Tgfb1-/-;
Rag2-/-) were characterized by up-regulation of genes associ-
ated with inflammatory and innate immunological responses,
and intestinal epithelial cell differentiation. Recent studies
have indicated that chronic inflammation caused either by
infection with Helicobacter pylori [32] or Helicobacter
17 734 Global Immune response, cellular movement, 
hematological system development and function, 
cell-to-cell signaling and interaction, immune and 
lymphatic system development and interaction, 
tissue development, connective tissue disorders, 
inflammatory disease, cancer
Cell invasion (CD14, CTSB, CTSL, ETS1, FN1, 
FSCN, FST, INHBA, ITGB2, LOX, MMP2, MMP9, 
MMP11, MMP12, MMP13, MYLK, OSM, PLAU, 
RECK, RGS4, RUNX2, S100A4, SPP1, SULF1, 
TIMP3), adhesion of tumor cells (ADAM12, 
ANXA1, CCL3, CCL4, FN1, ICAM1, IL6, ITGA4, 
ITGB2, PLAU, SELE, THBS1), metastasis of 
carcinoma cell lines (CCL2, DAPK1, S100A4, 
TWIST1, WISP1), tumor cell spreading (FN1, 
PLAU, SNAI2, THBS1, TNC), progression of 
gastric carcinoma (APOE, COL1A1, COL1A2)
PS, ProbeSets.
Table 3 (Continued)
Detailed cluster analysis: differential and statistically significant biological functions in clusters C11-C17Genome Biology 2007, 8:R131
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ment in Smad3-/- and Tgfb1-/-; Rag2-/- mice, respectively.
The activation of canonical WNT signaling in AOM tumors
was identified using a between-tumor global median normal-
ization to gene expression data. However, when tumor sam-
ple expression was referenced to that of normal adult
intestinal tissue, many more genes are up-regulated, includ-
ing developmental genes that are not dependent on nuclear β-
catenin. That canonical WNT signaling-related genes are
altered similarly in both AOM and ApcMin/+ tumors suggests
biological similarities between the two models. In addition,
the relatively consistent programming within the AOM model
also emphasizes its value for examining the more complicated
genetics that result in strain-specific sensitivity to environ-
mental agents that induce cancer.
Activation of canonical WNT signaling leads to nuclear trans-
location of β-catenin and, through its interaction with LEF/
TCF, the regulation of genes relevant to embryonic develop-
ment and proliferation [16], as well as stem cell self-renewal
[33]. Consequently, the activated canonical WNT signaling
Human CRCs exhibit gene expression profile complexity consistent with significant tumor subclassesFigure 5
Human CRCs exhibit gene expression profile complexity consistent with significant tumor subclasses. Genes potentially able to distinguish cancer subtypes 
were identified from Affymetrix HG-U133 plus2 Genechip expression profiles by filtering for 3,285 probe sets that were top-ranked by raw expression 
and their differential regulation in at least 10 out of 100 human colorectal cancer tumors. Coordinately regulated transcripts and similarly behaving samples 
were identified via hierarchical tree clustering. Seven different gene clusters (C11-17) were identified that distinguished ten or more tumors from the 
other tumors. Gene clusters were found to be highly enriched for gene functions listed in Table 3. Data were processed using Robust Microarray Analysis 
(RMA) with expression value ratios depicted as the relative expression per probe set in each sample relative to the median of its expression across the 
100 CRCs. A striking heterogeneity of gene expression was observed, including metallothionein genes in cluster C15 previously shown to be predictive of 
microsatellite instability (indicated by asterisk), and C17 represented by 734 probesets rich in genes associated with extracellular matrix and connective 
tissue, tumor invasion and malignancy. Tissue groups: AC, adult colon; CRC, human CRC. Staging: nAC, normal colon; Dukes A-D, human tumors 
obtained from individuals. Clusters C11-C17 labeled to the right of the heatmap correspond to the K-means functional clusters listed in Table 3.
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nobserved in ApcMin/+ and AOM models suggests that tumors
may arise as a consequence of proliferation of the stem cell or
'transient amplifying' compartment. In the colonic crypt, loss
of TCF4 [34] or DKK1 over-expression [35] promotes loss of
stem cells, suggesting that canonical WNT signaling is
required for the maintenance of the intestinal stem cell com-
partment [34-36]. Conversely, increased nuclear β-catenin/
TCF4 activity imposes a crypt progenitor phenotype on tumor
cells [18]. In this study, we identified transcriptional activa-
tion of the canonical WNT signaling pathway in tumors from
ApcMin/+ and AOM mice. This was confirmed by immunohis-
tochemistry (Figure 2b).
In colon tumors and perhaps intestinal stem cells, activation
of canonical WNT signaling promotes a hyperproliferative
state. Proliferation-related characteristics of nuclear β-cat-
enin-positive tumors include increased expression of CCND1,
MYC, PCNA [18], and Sox4 [16]. These genes were also
identified as a component of our nuclear-β-catenin-positive
signatures. In turn, increased MYC decreases intestinal cell
differentiation by binding to and repressing the Cdkn1a (cod-
ing for p21CIP1/WAF1) promoter [37], the gene encoding Wnt-
inhibitory factor Wif1, the gene encoding the negative regula-
tor of WNT Naked1 [38], and the gene encoding the Tak1/
Nemo-like kinase, Nlk [39]. Wif1 displays a graded expres-
sion in colonic tissue, with higher expression in the stem cell
compartments and lower expression in the more differenti-
ated cells at the luminal surface, suggesting that Wif1 may
contribute to stem cell pool maintenance independent of
WNT signaling inhibition. [40].
Canonical WNT signaling not only governs intestinal cell pro-
liferation, but also cell differentiation and cell positioning
along the crypt-lumen axis of epithelial differentiation.
Increased canonical WNT signaling activity enhances
MATH1-mediated amplification of the gut secretory lineages
[41]. Canonical WNT signaling also influences cell
positioning by regulating the gradient of EPHB2/EPHB3 and
EPHB1 ligand expression [42,43]. Together, our data suggest
a complex imbalance of crypt homeostasis due to enhanced
canonical WNT activity.
Our results indicate that tumors arising in response to abnor-
mal TGFβ1/SMAD signaling [14,44] are similar to one
another in their specific gene signatures and broadly distinct
from those with activated canonical WNT signaling by their
absence of nuclear β-catenin. Unique to the dysregulated
TGFβ1/SMAD4 signaling models is the strong signature of an
immunologically altered state, with up-regulation of genes
determining immune and defense responses, such as Il18,
Irf1 and mucin pathway-associated genes. Again, these
tumors are usually characterized by a strong inflammatory
component when evaluated histopathologically, even in the
absence of T- and B-cells such as in the Tgfb1-/-; Rag2-/- back-
ground.
As shown in Figure 2a, the microarray patterns of gene
expression for AOM and ApcMin/+ tumors are mirror images
of those for Tgfb1-/-; Rag2-/- tumors. It is perhaps not surpris-
ing that combining these two transcriptional programs
results in increased number and invasiveness of colonic
tumors as recently reported for ApcMin/+ mice crossed to
Smad3-/- mice [45]. Moreover, combined activation of canon-
ical WNT signaling and inhibition of TGFβ signaling also
results in more advanced intestinal tumors in Apcdelta716/+;
Smad4+/- mice [46], and intestine-specific deletion of the
type II TGFβ receptor in Apc1638N/wt mice [47].
The findings that shared over-expressed signatures are iden-
tifiable in all four mouse models of CRC, which are also rep-
resentative of the majority of embryonic colonic over-
expressed signatures, and that these signatures are also
present in all human CRCs, suggest that colon tumors may
arise independently of canonical WNT signaling status. A
likely candidate to impart this oncogenic signaling is Myc,
which is an embryonic up-regulated transcript that is also
upregulated in all human CRCs and mouse tumor models
independently of nuclear β-catenin status.
Embryology provides insight into the biology of mouse 
and human colon tumors
It has long been suggested that cancer represents a reversion
to an embryonic state, partly based upon the observation that
several oncofetal antigens are diagnostic for some tumors
[48,49]. To assess the embryology-related aspects of tumori-
genesis and tumor progression in CRC, we analyzed and com-
pared the transcriptomes of normal mouse colon
development and models of CRC. Our data show that devel-
opmentally regulated genes represent approximately 56% of
mouse tumor signatures, and that the tumor signatures from
the four mouse models recapitulate approximately 85% of
developmentally regulated genes.
There are at least two regulatory programs that determine the
expression of developmental genes by mouse tumors (Figures
2, 4, and 8). The simpler program is evident by the over-
expression of the earliest genes of colon development by the
nuclear β-catenin-positive models. The more subtle program
could be detected only in reference to adult colon and is
highly shared by nuclear β-catenin-negative models. This
program, though modified by nuclear β-catenin status, is rep-
resented by a large scale over-expression of developmentally
expressed genes in tumors that are both positive and negative
for canonical WNT signaling. Genes found within this signa-
ture have a large overlap with those present in the colon at
later developmental stages (E16.5-E18.5).
How do genes tightly regulated during mouse colon develop-
ment become activated in colon tumors? While activated
canonical WNT signaling imparts a strong influence, its
absence in Tgfb1-/-; Rag2-/- and Smad3-/- tumors, as deter-
mined by the absence of nuclear β-catenin, did not preventGenome Biology 2007, 8:R131
R131.16 Genome Biology 2007,     Volume 8, Issue 7, Article R131       Kaiser et al. http://genomebiology.com/2007/8/7/R131Figure 6 (see legend on next page)
(a)
2,
21
6 
fe
a
tu
re
s
(c)
3.0
0.3
1.0
  
Observed Expected Observed Expected
Ortholog genome 8,621 2,718 n/a 2,365 n/a
Ov er-expressed 2,212 1,080* 697 549*** 607
Under-expressed 737 156** 232 431**** 202
Embryonic colon
Human CRCs
Ov er-expressed Under-expressed
8,
62
1 
fe
a
tu
re
s
3.0
0.3
1.0
ED
LD
nACA
M
S
T CRC
C22
C18
C19
C23
C20
C21
ED
LD
nACA
M
S
T CRC
(b)
Ge
n
e
 e
xp
re
ss
io
n
 r
e
la
tiv
e
 
to
 
a
du
lt
co
lo
n
Ge
n
e
 e
xp
re
ss
io
n
 r
e
la
tiv
e
 
to
 
a
du
lt
co
lo
nGenome Biology 2007, 8:R131
http://genomebiology.com/2007/8/7/R131 Genome Biology 2007,     Volume 8, Issue 7, Article R131       Kaiser et al. R131.17
co
m
m
ent
review
s
repo
rts
refereed research
depo
sited research
interactio
ns
info
rm
atio
nthe large scale activation of developmental/embryonic gene
expression. One mechanism may be through epigenetic alter-
ations. In human CRCs, these types of alterations in gene
expression programs [50] suggest a link between cellular
homeostasis and tumorigenesis. The recruitment of histone
acetyltransferases and histone deacetylases (HDACs) are key
steps in the regulation of cell proliferation and differentiation
during normal development and carcinogenesis [51].
Induction of Hdac2 expression occurs in 82% of human CRCs
as well as in tumors from ApcMin/+ mice [19]. Alternatively,
common regulatory controls may operate in parallel growth
and differentiation/anti-diifferentiation pathways such that a
single or small subset of regulators, such as MYC or one or
more micro RNAs, may be responsible for the control of
multiple pathways. Indeed, consistent with our observation
of nuclear β-catenin-independent activation of Myc in all
mouse models and across the board for human CRC, deletion
of Myc has recently been demonstrated to completely abro-
gate nuclear β-catenin-driven small bowel oncogenesis in
mouse models [52].
Comparative analysis reveals underlying development-
related signatures in human CRCs
As shown in Figure 5, considerable and intriguing heteroge-
neity of human CRC is observed among genes highly relevant
for differential malignant behavior. However, employing
between-tumors normalization and referencing strategies
prevents the detection of gene expression patterns that are
shared between tumors. Using the adult normal colon as a
reference, as shown in Figure 6, a large fraction of differential
gene expression relative to adult colon could be demonstrated
that recapitulated developmental gene expression by virtue of
both activating embryonic colon gene expression and failing
to express genes associated with normal colon maturation.
Within these developmentally regulated gene sets, our analy-
ses revealed little evidence of CRC subsets, including those
suggestive of nuclear β-catenin negative tumors that might
approximate the Smad3-/- and Tgfb1-/-; Rag2-/- signature.
Our inability to identify distinct subclasses with respect to
developmental genes in the human CRCs is perhaps not sur-
prising in that over 80% of microsatellite-unstable (MSI+)
CRCs from HNPCC families exhibit nuclear β-catenin [53]. In
addition, within the developmental genes, little evidence was
apparent for signatures related to MSI+ tumors, often associ-
ated with HNPCC, although some of this type of signature was
perhaps apparent in the median normalized depiction of the
tumors as highlighted in Figure 5.
This report constitutes a comprehensive molecular evalua-
tion and comparison of mouse and human colon tumor gene
expression profiles. We have greatly improved our ability to
compare tumor gene expression profiles between mouse and
human tumors by using a referencing strategy in which gene
expression levels in the tumor samples are analyzed in rela-
tion to gene expression in corresponding normal colon epi-
thelium. This approach has revealed that gene expression
patterns are both shared and distinct between mouse models
and human CRCs. Although several recent studies have sug-
gested that tumors recapitulate embryonic gene expression
[16,27,54,55], the present study demonstrates the magnitude
of this similarity.
Finally, our results suggest that comparisons made between
mouse tumor models, developing embryonic tissues, and
human CRCs provides a powerful biological framework from
which to observe shared and unique genetic programs associ-
ated with human cancer. While ortholog-gene based analyses
have been used previously to obtain direct comparison of the
molecular features of mouse and human hepatocellular carci-
nomas [56], our results provide striking support for the
Both human CRCs and mouse colon tumors reactivate an embryonic gene signatureFigure 6 (see previous page)
Both human CRCs and mouse colon tumors reactivate an embryonic gene signature. When human and murine tumors are compared, they both broadly 
re-express an embryonic gene expression pattern. Gene expression profiles from the mouse tumor models and human CRC samples were combined into 
a single non-redundant gene ortholog genome table structure and subjected to comparative profile analysis. Informative probe-sets from human and 
mouse platforms were selected, mapped to corresponding ortholog genes, and used to populate a table in which normalized expression for each gene is 
relative to normal adult colon. (a) Heatmap plot for all cross-species gene orthologs both present and successfully measured on both the Affymetrix Hg-
U133 and Vanderbilt Mouse NIA 20 K microarrays (n = 8,621 features). This representation suggests that a large number of human CRC signatures exhibit 
similar behaviors in the mouse tumors and during embryonic mouse colon development (sidebar: 1,080 (red) and 431 (green) gene lists from (b)). (b) 
Based on results in (a), four separate gene lists were generated with criteria of over- or under-expression in development or over-expression or under-
expression in human CRCs (2,718, 2,365, 2,212, and 737, respectively, with the overlaps shown as a sidebar in (a); red, 1,080 transcripts, and green, 431 
transcripts). Genes over-expressed and under-expressed in embryonic mouse colon and human CRCs were found to be over-represented as determined 
by Fisher's exact test analysis (*p < 7 × 10-88, **p < 1 × 10-76, ***p < 5 × 10-4, ****p < 1 × 10-76). (c) Heatmap plot of all genes co-regulated in human CRCs 
and during early (ED) and late (LD) mouse embryonic colon development (n = 2,216 features). Six predominant clusters (C18-C23) characterize the 
transcriptional relationship between human CRC and mouse colon tumor models and embryonic development. Two clusters (C20 and 21) primarily 
distinguish human CRCs from murine tumors (A, M, S and T). For example, CRC up-regulated transcripts that are either developmentally up- or down-
regulated are represented by cluster C22 (n = 860 features) and clusters C21/C23 (n = 142 features), respectively. Conversely, CRC down-regulated 
transcripts that are either down- or up-regulated during development are shown in clusters C18/C19 (n = 258 features) and cluster C20 (n = 42 features), 
respectively. Interestingly, while approximately 80% and approximately 60% of genes up- and down-regulated in both human CRCs and mouse 
development were also up- and down-regulated in tumors from the various mouse models, several clusters provide very interesting exceptions: cluster 
C20 comprises genes down-regulated in human CRCs that are routinely over-expressed in mouse tumors and development; cluster C21 comprises genes 
robustly expressed in human CRC that are rarely expressed in embryonic colon or murine tumors. Sample groups: ED, early development (E13.5-E15.5); 
LD, late development (E16.5-E18.5); A, AOM-induced; M, ApcMin/+; T, Tgfb1-/-; Rag2-/-; S, Smad3-/-. Tissue groups: AC, adult colon; CRC, human CRC. 
Staging: nAC, normal colon.Genome Biology 2007, 8:R131
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Detailed cluster analysis: differential and statistically significant biological functions in clusters C18-C23
Cluster no. Number of PS Reference Pattern Biology Example genes
18 258 Adult colon Down (D); down 
(CRC); down 
(A/M/S/T)
Lipid metabolism, molecular transport, 
cell death, cancer, cellular movement, 
drug metabolism, lipid metabolism, 
digestive system development and 
function, small molecule biochemistry, 
endocrine system development and 
function, neurological disease
Gut epithelium differentiation (CA4, 
CA12, CBR1, CHGB, KLF4, KLF9, 
MCOLN2, SST, TFF3), apoptosis/cell 
death (CYCS, GSN, KITLG, SST, TFF3, 
TGFA), cytolisis/crypt damage (ABCB1, 
KLKR1, PTGER4), formation of aberrant 
crypt foci (NR5A2, PTGER4), drug 
transport (ABCB1, ABCG2), migration 
of tumor cells (EDG2, KITLG, SST, 
TGFA), quantity of colonocytes 
(GUCA2A)
19 42 Adult colon Up (D); down 
(CRC); down 
(A/M/S/T)
Digestive system development and 
function, cancer, small molecule 
biochemistry, reproductive system 
development and function, organ 
morphology
Colon and midgut development 
(EDNRB), gastrointestinal stromal 
tumor (KIT), apoptosis of mesothelioma 
cells (KIT), melanocyte differentiation 
(EDNRB, KIT), inhibition and 
morphology of melanoma cells (HSPE, 
LSP1), adhesion of lymphoma cells 
(HSPE)
20 91 Adult colon Up (D); down 
(CRC); up
(A/M/S/T)
Cell death, hematological disease, 
immunological disease, cell-to-cell 
signaling and interaction, hematological 
system development and function, 
immune response, cancer, cell 
morphology, tissue development, 
gastrointestinal disease
Apoptosis of colon carcinoma, cells 
(BCL2), apoptosis of lymphoma cell lines 
(BCL2, IGFBP4, MAP4K1, PDGFRA), 
cell-cell contact of endothelial cells 
(STAB1), lymphocyte quantity (BCL2, 
CCR7, CD28, ITGB7, ITK, MUC1, 
WNT4), proliferation of lymphocytes 
(CD28, ITK), gastrointestinal stromal 
tumor (PDGFRA), metastasis (CD28, 
ENPP2, FKBP1A), transmembrane 
potential of mitochondria (BCL2, CD28, 
EYA2, LGALS2, MUC1)
21 313 Adult colon Down (D); up 
(CRC); down 
(A/M/S/T)
Cell death, nervous system development 
and function, drug metabolism, small 
molecule biochemistry, cancer, cell 
cycle, cellular growth and proliferation, 
tissue development
Melanocyte survival (RB1), proliferation 
of neuronal progenitor cells (ATM, 
VEGF), heparin binding (PRNP, TNC, 
VEGF), dopamine formation (TH), drug 
resistance (ABCC1), quantity of tumor 
cell lines (LIF, PIK3R1, RB1, TIMP3, 
VEGF), transformation (FOXO3A), 
malignancy of astrocytoma (TNC), 
tumor vascularization (PTEGS, VEGF), 
growth of sarcoma cell lines (TIMP3), 
tissue proliferation (GRP, KRIT1, RB1, 
RBL2)
22 860 Adult colon Up (D); up 
(CRC); up 
(A/M/S/T)
Cell proliferation, cancer, DNA 
replication/recombination/repair, cell 
cycle progression and mitosis, cellular 
movement, connective tissue 
development and function, tumor 
morphology; purine and pyrimidine 
metabolism, folate metabolism
Cell transformation (Myc), mismatch 
repair (HMGB1, MSH2, MSH6, PCNA), 
arrest in mitosis (BIRC5, BUB1B, 
CDC2.CHEK1, CSE1L, MAD2L1, MIF, 
PLK1), migration/cytokinesis (ANLN, 
CDC42, FN1, ITGB5, MSF, SPARC, 
TOP2A), survival (AKT2, APEX1, 
BIRC5), gastric carcinoma progression 
(COL1A1, FUS), folate metabolism 
(MTHFD1, MTHFD2)Genome Biology 2007, 8:R131
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nhypothesis that cancer represents a subversion of normal
embryonic development. By inclusion of detailed mouse
embryonic and developmental profile information, our
results have revealed critical similarities and differences
between the mouse and human tumors that are particularly
revealing of oncogenic and tumor suppressor programs, some
genes from which should be useful for development of
diagnostic biomarkers and identification of therapeutic tar-
gets and pathways.
Materials and methods
Mouse models, human CRC patients and tumor 
collection
Mouse tumors
All tumors were isolated as spontaneously occurring lesions
in ApcMin/+ [57], Smad3-/- [58], and Tgfb1-/-; Rag2-/-, col-
lected at three-to-nine months of age depending on the model
(for a review, see [6]). The only exceptions were two ApcMin/+
tumors, UW_3_2778 and UW_6_2748, that were 13 and 14
months and the three Tgfb1-/-; Rag2-/- tumors, all five of
which had histological features of locally invasive carcinoma
[7]. Three- to four-month old mice from various AXB recom-
binant inbred lines were treated with AOM doses chosen for
enhancement of inter-strain differences in susceptibility [11].
Mice were given four weekly i.p. injections of 10 mg AOM per
kg body weight, and tumors were collected six months after
the first injection. Animals were euthanized with CO2, colons
removed, flushed with 1× phosphate-buffered saline (PBS),
and laid out on Whatman 3 MM paper. A summary of the
mouse strains, mutant alleles and source laboratories is pre-
sented in Table 5. All tumors were obtained from the colon
only, the particular segment of which is indicated in the Gene
Expression Omnibus (GEO) database [59] reposited sample
information (GSE5261). The majority of Tgfb1-/-; Rag2-/- and
Smad3-/- tumors occur in the cecum and proximal colon and
all samples isolated for characterization were obtained from
there. In contrast, tumors isolated from ApcMin/+ and AOM
mice occurred predominantly in the mid- and distal colon. A
small portion of the tumor was placed in formalin for histol-
ogy, with the remainder finely dissected into RNAlater
(Ambion Inc., Austin, TX, USA) and stored at -20°C. Normal
adult colon RNA for reference was obtained from whole colon
samples harvested from ten eight-week-old C57BL/6 male
mice. The tissue was lysed in Trizol Reagent (Invitrogen Sys-
tems Inc., Carlsbad, CA, USA) and homogenized. Total RNA
was purified using a Qiagen kit (USA-Qiagen Inc., Valencia,
CA, USA).
Human samples: collection/biopsies, regulatory aspects, compliance 
and informed consents
Sample collection protocol and analyses at the H Lee Moffitt
Cancer Center and Research Institute have been described
previously [37]. Information collected with the samples for
this study includes solid tumor staging criteria for tumor,
nodes, and metastases (TNM), Dukes staging/presentation
criteria, pathological diagnosis, and differentiation criteria.
RNA isolation
All RNA samples were purified using Trizol Reagent from
finely dissected tumors and were subjected to quality control
screening using the Agilent BioAnalyzer 2100 (Agilent Tech-
nologies, Santa Clara, CA, USA).
Microarray procedures and data analysis
Mouse cDNA arrays
Mouse tumors were analyzed on Vanderbilt University
Microarray Core (VUMC)-printed 20 K mouse cDNA arrays,
composed principally of PCR products derived from three
sources: the 15 K National Institute of Aging mouse cDNA
library; the Research Genetics mouse 5 K set; and an addi-
tional set of cDNAs mapped to RefSeq transcripts. Labeling,
hybridization, scanning, and quantitative evaluation of these
two-color channel arrays were performed according to VUMC
protocols [60] using a whole mouse Universal Reference
standard (E17.5 whole fetal mouse RNA). Arrays were ana-
lyzed by GenePix version 3.0 (MDS Inc., Sunnyvale, CA,
USA), flagged and filtered for unreliable measurements, with
dye channel ratios corrected using Lowess and dye-specific
correction normalization as previously described [15].
Human Affymetrix oligonucleotide arrays
Human RNA samples were labeled for hybridization to
Affymetrix HG-U133plus2 microarrays using the Affymetrix-
23 142 Adult colon Down (D); up 
(CRC); up 
(A/M/S/T)
Connective tissue development and 
function, cell-to-cell signaling, 
development disorder, organismal injury 
and abnormalities, tumor morphology, 
hematological system development and 
function, immune and lymphatic system 
development and function, cancer
Cell transformation (ESR1, SRC), basal 
membrane disruption (MMP7), cell 
extension (ATF3, CD82, IL6, SRC), 
contact growth inhibition (JUN, IL6), 
osteocyte differentiation (IL6, JUN, 
SMAD6, SRC), cell cycle progression 
(ESR1, IER3, IL6, PSEN2), ERK/MAPK 
signaling (ESR1, ETS2, PPP1R10, 
PPP2R5C), development of tumor 
(CXCL6, ESR1, IER3, IL6, JUN), invasion 
of colon cancer cell lines (CD82, SRC), 
colon cancer (JUN, PDGFRL, SRC)
A, AOM-induced; M, ApcMin/+; PS, ProbeSets; S, Smad3-/-; T, Tgfb1-/-; Rag2-/-.
Table 4 (Continued)
Detailed cluster analysis: differential and statistically significant biological functions in clusters C18-C23Genome Biology 2007, 8:R131
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nrecommended standard labeling protocol (Small-scale
labeling protocol version 2.0 with 0.5 μg of total RNA;
Affymetrix Technical Bulletin). Microarrays were scanned
with MicroarraySuite version 5.0 to generate 'CEL' files that
were processed using the RMA algorithm as implemented by
Bioconductor [15].
Analysis strategy
The four different mouse models of CRC were compared for
model-specific differences, then compared to mouse colon
development stages, and then to human CRC samples (Figure
1). The mouse tumor sample array data are composed of Low-
ess-normalized Cy3:Cy5 labeling ratios of each individual
tumor sample versus a universal E17.5 whole fetal mouse ref-
erence RNA (described using MIAME guidelines in the NCBI
GEO database under series accession number GSE5261). The
first approach to referencing was to compare normalized
ratios across the tumor series. To do this, for each gene, the
Lowess-corrected ratio for each probe element (sample ver-
sus E17.5 whole fetal mouse reference) was divided by the
median ratio for that probe across the entire tumor sample
series. This is termed the median-per-tumor expression ratio
and was useful for identifying, clustering and visualizing dif-
ferences that occur between the different tumor samples.
Since we previously collected mouse expression data for nor-
mal E13.5-E18.5 colon samples from inbred C57BL/6J and
outbred CD-1 mice [15] using the identical E17.5 whole fetal
mouse reference, this allowed us to combine the data directly.
Differential expression profiles in the tumors were combined
with relative developmental gene expression levels by direct
comparisons of ratios determined within each experimental
series. Initial comparisons were made between median nor-
malized tumor data to gene expression levels observed in the
E13.5-E18.5 and adult (eight week post-natal) colon samples,
which were referenced to either E13.5 samples or to the adult
colon. The latter approach subsequently allowed for the
broadest comparison of mouse and human data using gene
ortholog mapping. Correlated phenomena could be observed
from any of the different referencing strategies.
Inter-organism gene ortholog and inter-platform comparison strategy
Pairs of human and mouse ortholog genes (12,693) were
curated using the Mouse Genome Informatics (MGI; The
Jackson Laboratory) [61] and National Center for Biotechnol-
ogy Information (NCBI) Homologene [62] databases. Indi-
vidual microarray elements or features were mapped to these.
The concatenated human and mouse RefSeq IDs was used as
the composite ID for the orthologous gene pair in the ortholog
genome definition. NIA/Research Genetics mouse cDNAs
were mapped to human orthologs using a variety of resources,
usually via the Stanford Online Universal Reference resource
[63]. Gene transcript assignments were made unique by
choosing the longest corresponding transcript. To map the
Affymetrix human and mouse array data into the ortholog
genome, we used a sequence matching approach. First, we
obtained human and mouse transcript sequences from
RefSeq [64] and probe sequences from the manufacturer's
website [65]. Next, we computed all perfect probe-transcript
pairs. We excluded probes that matched multiple gene sym-
bols but accepted probes that matched multiple transcripts.
Probe sets were assigned to represent a given transcript if at
least 50% of the perfect match probes of the probe set
matched to that transcript. The newly assigned transcript
identifiers were then used to map probe sets to ortholog
genes. Since some transcripts have multiple probe-set repre-
sentations on both the Affymetrix and cDNA microarrays to
one ortholog identifier, we employed an ad hoc strategy to use
the average of those probe sets or cDNAs that exhibited con-
sistent regulation across a sample series. In such cases, the
signals of the regulated probe sets that were interpreted as
being in agreement were averaged and assigned to the corre-
sponding ortholog. We excluded probe sets or cDNAs that we
were aware corresponded to non-transcript genomic
sequence as tested using BLAT at the UCSC Goldenpath web-
site [66].
Mouse-human RefSeq gene ortholog assignments can be
found at GenomeTrafac [67,68]. All ortholog assignments
and cross-species mapping annotations were incorporated
into annotations associated with the Affymetrix HG-U133
plus2.0 genome. Gene expression ratios obtained for the
mouse samples were then represented as expression values
within the human platform for all of the probe sets that
mapped to the corresponding mouse gene ortholog. Data for
the primary human sample series, as well as the combined
mouse-human data sets, are available in the Cincinnati Chil-
dren's Hospital Medical Center microarray data server [69] in
the HG-U133 genome under the KaiserEtAl_2006 folders
The up-regulated signature in tumors from ApcMin/+ (M) and AOM (A) models (cluster C6, Figure 2) is enriched with genes associated with the activation of the canonical WNT signaling pathway, as determined by nuclear β-catenin positivi yFigure 7 (see prev ous p ge)
The up-regulated signature in tumors from ApcMin/+ (M) and AOM (A) models (cluster C6, Figure 2) is enriched with genes associated with the activation of 
the canonical WNT signaling pathway, as determined by nuclear β-catenin positivity. (a) Schematic diagram of the canonical WNT signaling pathway 
showing elements present in cluster C6 (gene symbols with gray background). Key elements of this pathway (Ctnnb1, Lef1, Tcf and Myc) are outlined in 
blue. (b) Relative gene expression for MYC and SOX4 is plotted for individual murine and human tumors. The relative expression level of MYC and SOX4 
is normalized to adult colon. Note that whereas Sox4, a canonical WNT target gene, is expressed at high levels in all human CRCs, A/M tumors and during 
embryonic mouse colon development, it is not expressed in Smad3-/- (S) and Tgfb1-/-; Rag2-/- (T) tumors (black). In contrast, MYC is over-expressed in all 
human and murine tumors and during colonic embryonic development (red), irrespective of the activation of canonical WNT signaling, as determined by 
nuclear β-catenin positivity (Figure 2). Tissue groups: as above and: nAC-m, normal adult mouse colon; nAC-h, normal adult human colon; Dev, developing 
mouse colon.Genome Biology 2007, 8:R131
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n('guest' login; all cross-platform ortholog gene identifiers are
contained as annotation fields within the HG-U133 genome
table).
Statistical and data visualization approaches
Most normalization, expression-level referencing, statistical
comparisons, and data visualization were performed using
GeneSpring v7.0 (Silicon Genetics-Agilent (part of Agilent
Technologies). Fisher's exact test was performed online at the
MATFORSK Fisher's Exact Test server [70]. To identify dif-
ferentially expressed features between two or more classes,
we applied GeneSpring's Wilcoxon-Mann-Whitney or the
Kruskal-Wallis test, respectively. For three or more classes,
the initial non-parametric test was followed by the Student-
Newman-Keuls post-hoc test. Results from the primary anal-
yses were corrected for multiple testing effects by applying
Benjamini and Hochberg false discovery rate (FDR) correc-
tion [71]. In general, due to the referencing strategies, good
platform technical performances, and moderately low within-
group biological variation of gene expression, stringent cut-
offs could be used, that is, the FDR level of significance was
set between FDR < 5.10-5 and FDR < 5.10-4. K-means cluster-
ing was performed using the GeneSpring K-means tool and
the Pearson correlation similarity measure.
Ontology-based analysis of gene cluster-associated 
functional correlates
Gene expression clusters were analyzed for the occurrence of
multiple genes involved in related gene function categories by
comparing each list of coordinately regulated clustered genes
to categories within Gene Ontology, pathways, or literature-
based gene associations using GATACA [72], Ontoexpress
[73], and Ingenuity Pathway Analysis, version 3 (IPA, Inge-
nuity Systems, Redwood City, CA, USA) [74]. To do this, each
cluster indicated in Figures 2, 4, 5, 6 and 8 was converted to a
list of gene identifiers, uploaded to the application, and exam-
ined for over-representation of multiple genes from one or
more molecular networks, or functional or disease associa-
tions as developed from literature mining. Networks of these
focus genes were algorithmically generated based on the rela-
tionships of individual genes as derived from literature review
and used to identify the biological functions and/or associ-
ated pathological processes most significant for each gene
cluster. Fisher's exact test was used to calculate a p value esti-
mating the probability that a particular functional classifica-
tion or category of genes is associated with a particular
pattern or cluster of gene expression more than would be
expected by chance. For each cluster, only the top significant
functional classes and canonical pathways are shown. Figure
An integrated view of colon cancer transcriptional programs provides novel insight into neoplasiaFigur  8 (see previous page)
An integrated view of colon cancer transcriptional programs provides novel insight into neoplasia. Murine colon tumor adenomas and human CRCs both 
show adoption and dysregulation of signatures tightly controlled during embryonic mouse colon development. The use of etiologically distinct mouse 
models of colon cancer allows for the identification of models that resemble different stages of embryonic mouse colon development and that are 
recapitulated by specific tumor types. (a) All tumors exhibit large-scale activation of developmental patterns. Nuclear β-catenin-positive (ApcMin/+ and 
AOM) tumors map more strongly to early development stages during (more proliferative, less differentiated), whereas nuclear β-catenin-negative (Tgfb1-/-
; Rag2-/- and Smad3-/-) tumors map more strongly to later stages consistent with increased epithelial differentiation. (b) Overall representation of the 
relationship of mouse colon tumor models and human CRC to development and non-developmental expression patterns. Gene expression clusters 
mapped to the progression of adenomatous and carcinomatous transformation identified in Figures 5 and 6 are shown as the clusters of genes whose 
expression is either gained or lost associated with the stage of progression. For example normal development could be considered as 'subverted' if there 
is an absence of expression of genes normally expressed at high level in the developing colon that fail to be expressed in tumors (for example, C18, C19), 
or that are activated in tumor but not normally expressed in development (C20). Upregulated clusters are enriched for genes with known oncogenic 
functions and down-regulated clusters for genes associated with tumor suppression. Both mouse colon tumor models and human CRC share in the 
activation of embryonic colon expression (C22), or partially overlap (C23, dotted lines) the loss or repression of adult differentiation-associated genes 
(C19), and the loss of tumor suppressor genes (C18). Many human CRCs also lack the expression of additional tumor suppressor programs and gain the 
expression of oncogenes that are not over-expressed during normal developmental morphogenesis (C21).
Table 5
Mouse models of colon cancer
Model Mm strain N Tumor-generating laboratory
Azoxymethane (AOM) A × B 14 Threadgill
ApcMin/+ (SWR × B6) F1 2 Dove
ApcMin/+ (BR × B6) F1 2 Dove
ApcMin/+ C57BL/6 5 Groden
Smad3-/- 129 6 Graff
Smad3-/- 129 7 Coffey
Tgfb1-/-; Rag2-/- C57BL/6 3 Doetschman
Tumors from four established mouse models of CRC (ApcMin/+, AOM, Smad3-/- and Tgfb1-/-; Rag2-/- were analyzed. The table provides details on the 
mouse strains used for the four models, as well as information on the number of samples generated per model and sample-originating laboratory.Genome Biology 2007, 8:R131
R131.24 Genome Biology 2007,     Volume 8, Issue 7, Article R131       Kaiser et al. http://genomebiology.com/2007/8/7/R1317a shows a diagram of the canonical WNT signaling pathway
and an associated-gene network that was a top-ranked
association of the clusters that exhibited significant over-
expression in AOM and ApcMin/+ versus Smad3-/- and Tgfb1-/-;
Rag2-/- mouse models. Genes or gene products are repre-
sented as nodes, and biological relationships between nodes
are represented as edges (lines). All edges are supported by at
least one literature reference from a manuscript, or from
canonical information stored in the Ingenuity Pathways
Knowledge Base.
qRT-PCR
To confirm the validity of data normalization and referencing
procedures as well as the cDNA gene assignments of the
printed arrays used in the microarray analyses, we used qRT-
PCR to measure relative levels of nine genes found by micro-
array data analysis to be differentially expressed (FDR <
5.10-5) in tumors from ApcMin/+ and Smad3-/- mice. Total
RNAs from C57BL6 ApcMin/+ and 129 Smad3-/- tumor sam-
ples (20 μg) were reverse-transcribed to cDNA using the High
Capacity cDNA Archive Kit (oligo-dT primed; Applied Biosys-
tems, Foster City, CA, USA). qRT-PCR reactions (20 μl) were
set up in 96-well MicroAmp Reaction Plates (Applied Biosys-
tems) using 10 ng of cDNA template in Taqman Universal
PCR Master Mix and 6-FAM-labeled Assays-on-Demand
primer-probe sets (Applied Biosystems). Reactions were run
on an MX3000P (Stratagene, a division of Agilent Technolo-
gies) with integrated analysis software. Threshold cycle num-
bers (Ct) were determined for each target gene using an
algorithm that assigns a fluorescence baseline based on meas-
urements prior to exponential amplification. Relative gene
expression levels were calculated using the ΔΔCt method [75],
with the Gusb gene as a control. Fold-change was determined
relative to expression in normal adult colon from two C57BL/
6J mice.
Immunohistochemistry
Immunohistochemical procedures were performed as
described [15]. ApcMin/+ and Smad3-/- colon tumors were rap-
idly dissected, fixed in 4% paraformaldehyde, and embedded
in paraffin before cutting 10 μm thick sections. Antigen
retrieval was performed by boiling for 20 minutes in citrate
buffer, pH 6.0. Sections were treated with 0.3% hydrogen
peroxide in PBS for 30 minutes, washed in PBS, blocked in
PBS plus 3% goat serum and 0.1% Triton X-100, and then
incubated with primary antibodies and HRP-conjugated goat
anti-rabbit secondary antibody (Sigma, St Louis, MO, USA).
Antigen-antibody complexes were detected with a DAB per-
oxidase substrate kit (Vector Laboratories, Burlingame, CA,
USA) according to the manufacturer's protocol.
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